ReviewWorld journal of gastroenterology2007
Utility of serological markers in inflammatory bowel diseases: gadget or magic?
Review in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- TNFRSF1B Is Associated with ANCA in IBD.Inflammatory bowel diseases · 2016Pooled it
- Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.Inflammatory bowel diseases · 2012Pooled it
- Oral and upper gastrointestinal Crohn's disease: new perspectives on pathogenesis and clinical management.Frontiers in cell and developmental biology · 2026Review
- Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.Journal of Crohn's & colitis · 2025Article
- Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review.International journal of molecular sciences · 2024Review
- Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity.Medicines (Basel, Switzerland) · 2020Review
- Article
- ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation.BMC gastroenterology · 2018Article
- Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance.Frontiers in immunology · 2018Review
- Observational
- Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- The Immunological Basis of Inflammatory Bowel Disease.Gastroenterology research and practice · 2016Review
- Clinical Utility of Biomarkers in IBD.Current gastroenterology reports · 2015Review
- Gastrointestinal Behçet's disease: a review.World journal of gastroenterology · 2015Review
- Laboratory markers in ulcerative colitis: Current insights and future advances.World journal of gastrointestinal pathophysiology · 2015Review
- Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?World journal of gastroenterology · 2014Review
- New serological markers in pediatric patients with inflammatory bowel disease.World journal of gastroenterology · 2014Review
- Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.Inflammatory bowel diseases · 2014Article
- Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.World journal of gastroenterology · 2014Article
- Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.Journal of immunology research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.